key: cord-0896678-izrr0lri authors: Abdel-Sater, F.; Younes, M.; Nassar, H.; Nguewa, P.; Hamze, K. title: A Rapid and Low-Cost protocol for the detection of B.1.1.7 lineage of SARS-CoV-2 by using SYBR Green-Based RT-qPCR date: 2021-01-29 journal: nan DOI: 10.1101/2021.01.27.21250048 sha: a557eb9119a0b7011e19aca8ef49044a19defe1d doc_id: 896678 cord_uid: izrr0lri Background: The new SARS-CoV-2 variant VUI (202012/01), identified recently in the United Kingdom (UK), exhibits a higher transmissibility rate compared to other variants, and a reproductive number 0.4 higher. In the UK, scientists were able to identify the increase of this new variant through the rise of false negative results for the spike (S) target using a three-target RT-PCR assay (TaqPath kit). Methods: To control and study the current coronavirus pandemic, it is important to develop a rapid and low-cost molecular test to identify the aforementioned variant. In this work, we designed primer sets specific to SARS-CoV-2 variant VUI (202012/01) to be used by SYBR Green-based RT-PCR. These primers were specifically designed to confirm the deletion mutations {Delta}69/{Delta}70 in the spike and the {Delta}106/{Delta}107/{Delta}108 in the NSP6 gene. We studied 20 samples from positive patients, 16 samples displayed an S-negative profile (negative for S target and positive for N and ORF1ab targets) and four samples with S, N and ORF1ab positive profile. Results: Our results emphasized that all S-negative samples harbored the mutations {Delta}69/{Delta}70 and {Delta}106/{Delta}107/{Delta}108. This protocol could be used as a second test to confirm the diagnosis in patients who were already positive to COVID-19 but showed false negative results for S-gene. Conclusions: This technique may allow to identify patients carrying the VUI (202012/01) variant or a closely related variant, in case of shortage in sequencing. As the pandemic of SARS-CoV-2 continues to affect the planet, researchers around the world are monitoring the virus and detecting acquired mutations that may lead to higher threats of spreading COVID-19 [1] . A new variant was recently reported in the UK as a Variant Under Investigation (VUI -202012/01), belonging to the B.1.1.7 lineage [2] . Its rate of transmission is estimated to be >70%, and its reproductive number (Ro) seems to be up to 0.4 higher [3] . This variant harbors 14 non-synonymous mutations, 6 synonymous mutations and 3 deletions [2, 3] . A wide variety of diagnostic tests have been used by high-throughput national testing systems around the world, to monitor the SARS-CoV-2 infection [4] . The arising prevalence of new SARS-CoV-2 variants such as B.1.1.7 has become of great concern, as most of the existing RT-PCR tests will not be able to specifically distinguish these new variants because they were not designed for such a purpose. Therefore, public health officials most rely on their current testing systems and their sequencing results to draw conclusions on the prevalence of new variants in their territories [2, 5] . An example of such cases has been seen in the UK. In fact, scientists were able to identify the augmentation of the B.1.1.7 SARS-CoV-2 variant infection in the population through an increase in the S-gene target failure in their three target gene assay (N+, ORF1ab+, S-) when using the Applied Biosystems TaqPath RT-PCR COVID-19 kit (Thermo Fisher Scientific, Waltham, USA) that included the ORF1ab, S, and N gene targets [1, 6, 7] . In 24 December 2020, Thermo Fisher Scientific confirmed that the S deletion Δ 69/Δ70 was in the area targeted by the TaqPath Kit. Whilst other variants with Δ 69/70 are also circulating worldwide, the absence of detection of the S gene target increasingly appears to be a highly specific marker for the new variant [2, 7] . In addition, the European CDC recommended that multi-target RT-PCR assays that included an S gene target affected by the deletions could be All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In 15 January 2021, in GISAID we found 374,613 SARS-CoV-2 sequences, among them 17,473 sequences belonged to the new variant (VUI 202012/01). It is important to notice that the cooccurrence of mutations Δ 69/Δ70 in the spike and Δ 106/Δ107/Δ108 in the NSP6, was present in this new variant. We then decided to use these two deletions as targets for our rapid and low-cost protocol, performing SYBR Green-Based RT-PCR. In this work, we propose primer sets that can be applied as a second step to confirm the diagnosis in cases that were already detected as positive to SARS-CoV-2. It is well known that confirmatory diagnosis based on specific diagnostic biomarkers remains a great challenge allowing the further control and eradication of infections including COVID-19 [10]. Therefore, this novel method may lead to specifically identify individuals carrying the Δ 69/Δ70 and the Δ 106/Δ107/Δ108 mutations. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 29, 2021. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 29, 2021. ; https://doi.org/10.1101/2021.01.27.21250048 doi: medRxiv preprint Quantitative RT-PCR was carried out using iTaq universal SYBR green super mix (Bio Rad). In In order to validate our method, we re-tested 20 samples that had been tested as positive for SARS-CoV-2 with Ct < 30, by the TaqPath kit. 16 samples with S-negative profile and four samples with S-positive profile ( Table 2) (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 29, 2021. Sequencing is the current gold standard diagnostic method to confirm the presence of any new variant, its efficient but a time consuming method and not accessible to all laboratories especially in developing countries. In this study, we have developed a rapid, low-cost, large-scale screening protocol for the detection of the deletions Δ 69/Δ70 and Δ 106/Δ107/Δ108. We hope that our efforts will be helpful and can contribute to the early detection of the new variant (VUI 202012/01), for the prevention of transmission and early intervention. This protocol should not be limited to this variant, but also for any other future variant to come, just by designing the appropriate primers. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 29, 2021. ; https://doi.org/10.1101/2021.01.27.21250048 doi: medRxiv preprint 1 2 Design of Specific Primer Set for Detection of B. 1.1. 7 SARS-CoV-2 Variant using Deep Learning 1.1. 7 in England: Insights from linking epidemiological and genetic data Investigation of novel SARS-COV-2 variant: Variant of Concern 202012/01. Public Health England Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations: COVID-19 genomics UK consortium Molecular diagnostic technologies for COVID-19: Limitations and challenges Two-step strategy for the identification of SARS-CoV-2 variants co-occurring with spike deletion H69-V70 This work was supported by the Lebanese University and Fundación La Caixa (LCF/PR/PR13/11080005), Fundación Caja Navarra, Fundación Roviralta, Ubesol, Inversiones Garcilaso de la Vega, COST Actions CA18217 and CA18218, and EU Project uncover (Grant/Award Number: 101016216). The authors have no conflicts of interest to declare. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 29, 2021. ; https://doi.org/10.1101/2021.01.27.21250048 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 29, 2021. ; https://doi.org/10.1101/2021.01.27.21250048 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 29, 2021. ; https://doi.org/10.1101/2021.01.27.21250048 doi: medRxiv preprint